Standout Papers
Citation Impact
Citing Papers
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
2012
Increased Mortality, Postoperative Morbidity, and Cost After Red Blood Cell Transfusion in Patients Having Cardiac Surgery
2007 Standout
Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
2017 Standout
Unexpected Increased Mortality After Implementation of a Commercially Sold Computerized Physician Order Entry System
2005 Standout
Randomized, Double-Blind, Placebo-Controlled Trial of Effects of Enteral Iron Supplementation on Anemia and Risk of Infection during Surgical Critical Illness
2009
Guidelines on the management of anaemia and red cell transfusion in adult critically ill patients
2012
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock
2004 Standout
Recent advances in the management of AL Amyloidosis
2015
Anemia and Blood Transfusion in Critically Ill Patients
2002 Standout
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)
2014
Duration of Red-Cell Storage and Complications after Cardiac Surgery
2008 Standout
Acute kidney injury
2012 Standout
Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial
2015
Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults
2007 Standout
Impact of allogenic packed red blood cell transfusion on nosocomial infection rates in the critically ill patient*
2002
Acute event‐related anaemia
2001
Prevalence and Control of Diabetes in Chinese Adults
2013 Standout
Erythropoiesis-stimulating Agents in Critically Ill Trauma Patients
2016
Management of Sepsis
2006
Trial Watch: Monoclonal antibodies in cancer therapy
2012
Amyloid diseases of the heart: current and future therapies
2012
Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use
2009
Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System
2014
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
2012
The Science of Stroke: Mechanisms in Search of Treatments
2010 Standout
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
Severe Sepsis and Septic Shock
2013 Standout
Health-related quality of life outcomes in chronic kidney disease
2010
Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?
2020
Enoxaparin for thromboprophylaxis after major trauma: Potential cost implications
2001
Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.
2013
Chronic kidney disease
2011 Standout
Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient
2016 Standout
Clinical practice guideline: Red blood cell transfusion in adult trauma and critical care*
2009
Amyloid heart disease: a brief review of treatment options
2012
Nutritional deficiencies and blunted erythropoietin response as causes of the Amemia of critical illness
2001
Prospective comparison of packed red blood cell–to–fresh frozen plasma transfusion ratio of 4
2012
A randomized, double-blind, placebo-controlled study to assess the effect of recombinant human erythropoietin on functional outcomes in anemic, critically ill, trauma subjects: the Long Term Trauma Outcomes Study
2011
The CRIT Study: Anemia and blood transfusion in the critically ill—Current clinical practice in the United States*
2004 Standout
Hydrocortisone Therapy for Patients with Septic Shock
2008 Standout
Systemic amyloidosis
2015 Standout
Prevention of Venous Thromboembolism
2004 Standout
Efficacy and Safety of Epoetin Alfa in Critically Ill Patients
2007
The immunology of stroke: from mechanisms to translation
2011 Standout
Ferrous Sulfate Supplementation Causes Significant Gastrointestinal Side-Effects in Adults: A Systematic Review and Meta-Analysis
2015 Standout
The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition
2016 Standout
A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis
2014
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis
2012
Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock*
2006 Standout
New cancer targets emerging from studies of the Von Hippel‐Lindau tumor suppressor protein
2010 StandoutNobel
Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis
2012
Transfusion Medicine
2001
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
2017 Standout
Guidelines for the Prevention of Intravascular Catheter-related Infections
2011 Standout
Early lactate clearance is associated with improved outcome in severe sepsis and septic shock*
2004 Standout
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017
Chronic Kidney Disease
2016 Standout
Impact of Erythropoiesis-Stimulating Agents on Energy and Physical Function in Nondialysis CKD Patients With Anemia: A Systematic Review
2009
Anemia of Chronic Disease
2005 Standout
Extracellular histones are major mediators of death in sepsis
2009 Standout
Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations
2015 Standout
Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
2016 Standout
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
2016 Standout
2011 Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines
2011 Standout
Melioidosis: Epidemiology, Pathophysiology, and Management
2005 Standout
Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China
2020 Standout
Evaluation and management of anemia in the elderly
2013
A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis
2012
Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity
2017 StandoutNobel
Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients
2011
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock
2004 Standout
Current Trends in Diagnosis and Management of Cardiac Amyloidosis
2013
New Choices for Central Venous Catheters
2003
Part 9: Post–Cardiac Arrest Care
2010 Standout
The effect of massive transfusion protocol implementation on pediatric trauma care
2016 StandoutNobel
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
2015 Standout
Proteasome dysfunction triggers activation of SKN-1A/Nrf1 by the aspartic protease DDI-1
2016 StandoutNobel
Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial.
2002
Dealing with limited overlap in estimation of average treatment effects
2009 StandoutNobel
Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: An overview
2007
A Randomized Trial of Protocol-Based Care for Early Septic Shock
2014 Standout
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
2013
Iron-Deficiency Anemia
2015 Standout
Systemic amyloidosis: novel therapies and role of biomarkers
2016
New choices for central venous catheters: potential financial implications.
2003
Dapagliflozin in Patients with Chronic Kidney Disease
2020 Standout
Inhibition of the oxygen sensor PHD2 in the liver improves survival in lactic acidosis by activating the Cori cycle
2015 StandoutNobel
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial
2012
Works of Christopher Enny being referenced
Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial
1999 Standout
Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa
2006
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects
2011
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
2011
An Open-Label, Randomized, Parallel-Group Study of Perioperative Epoetin Alfa Versus Standard of Care for Blood Conservation in Major Elective Spinal Surgery
2009
Improved Survival of Critically Ill Trauma Patients Treated With Recombinant Human Erythropoietin
2008
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
2011
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis
2014